Your session is about to expire
← Back to Search
MRI + PET Scans for Cognitive Impairment (BEACoN Trial)
BEACoN Trial Summary
This trial is studying how well MRI, PET, and cognitive testing work in detecting changes in the brain that may happen before someone shows symptoms of cognitive decline. They will also look at tau protein in the brain with a PET scan and an investigational drug.
BEACoN Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowBEACoN Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.BEACoN Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I speak English or Spanish fluently.You have been diagnosed with dementia or mild cognitive impairment by a specialist.You cannot have an MRI if you have certain medical implants or metal in your body. If you are pregnant or trying to get pregnant, you cannot participate.You do not have memory or thinking problems, and you score 27 or higher on a memory and thinking test.I am in good health with no conditions that could affect the study.You have had problems with alcohol or drugs in the past 2 years.I am 60 years old or older.I do not have uncontrolled diabetes, high blood pressure, nutritional deficiencies, or thyroid issues.You have had a lot of radiation exposure in the past or are pregnant.I can see and hear well enough for tests on a computer.I have a serious brain or nerve condition like Parkinson's or MS.You have a serious mental illness like schizophrenia, bipolar disorder, anxiety disorder, major depressive disorder, or attention-deficit hyperactivity disorder.You have been tested and found to have significant problems with memory or thinking.
- Group 1: Age 81+ ApoE e4-
- Group 2: Age 71-75 ApoE e4-
- Group 3: Age 60-65 ApoE e4+
- Group 4: Age 76-80 ApoE e4-
- Group 5: Age 66-70 ApoE e4-
- Group 6: Age 71-75 ApoE e4+
- Group 7: Age 81+ ApoE e4+
- Group 8: Age 76-80 ApoE e4+
- Group 9: Age 66-70 ApoE e4+
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this research project have any restrictions on who can participate?
"This trial is seeking 200 patients with Alzheimer's disease between the ages of 60 and 105. To be eligible, patients must meet the following criteria: Aged 60 and above;, Speaks fluent English or Spanish;, Visual and auditory acuity adequate for neuropsychological and computerized testing;, Good general health with no disease(s) expected to interfere with the study;, Willing and able to participate for the duration of the study and in all study procedures including MRI and PET;, Normal cognition defined as a Clinical Dementia Rating of 0 and a Mini-Mental State Examination score of 27 or higher."
Does the Tau PET scan using MK-6240 come with any risks for patients?
"There is both efficacy and safety data from previous clinical trials, so our team has given Tau PET scan using MK-6240 a score of 3."
Does this research project include people who are over 85 years old?
"The age range for individuals eligible to participate in this study are between 60 to 105 years old."
Share this study with friends
Copy Link
Messenger